Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Société Générale M&A Activity 2020

Apr 27, 2020

1671_mrq_2020-04-27_59ea298b-d9c6-4ea5-a9d9-6468c5f3fb07.html

M&A Activity

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 9868K

Societe Generale SA

27 April 2020

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1) Société Générale S.A.
Company dealt in Allergan plc
Class of relevant security to which the dealings being disclosed relate (Note 2) US$0.0001 ordinary shares
Date of dealing 24/04/2020

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long Short
Number (%) Number (%)
(1) Relevant securities 3,570,643 1.08 46,034 0.01
(2) Derivatives (other than options) 0 0.00 3,283,991 1.00
(3) Options and agreements to purchase/sell 58,500 0.02 0 0.00
Total *9,583,036 *2.91 3,330,025 1.01

* Include the holding of 5,953,893 shares on borrow products

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale Number of relevant securities Price per unit USD (Note 5)
Purchase 53 186.9
Purchase 17 186.24
Purchase 100 186.46
Purchase 100 186.56
Purchase 600 186.9
Purchase 100 186.65
Purchase 100 186.68
Purchase 200 186.515
Purchase 100 186.495
Purchase 100 186.55
Purchase 100 185.86
Purchase 100 185.25
Purchase 100 185.78
Purchase 100 185.505
Purchase 100 185.5
Purchase 100 186.57
Purchase 100 185.285
Purchase 100 185.43
Purchase 66 186.63
Purchase 100 185.47
Purchase 100 186.54
Purchase 91 185.42
Purchase 1,576 186.9
Purchase 19 186.542526
Sale 72 186.89125
Sale 100 185.87
Sale 100 185.31
Sale 1 185.77
Sale 99 185.76
Sale 100 185.77
Sale 42 186.895
Sale 100 186.36
Sale 59 186.9
Sale 100 186.11
Sale 15 186.42
Sale 100 185.41
Sale 100 186.9
Sale 5,943 186.9
Sale 100 185.76
Sale 100 186.3
Sale 100 186.55
Sale 985 186.9
Sale 2,955 186.9
Total Purchases 4,222
Total Sales 11,171

(b)      Derivatives transactions (other than options transactions)

Product name,

e.g. CFD
Nature of transaction

(Note 6)
Number of relevant securities

(Note 7)
Price per unit USD

(Note 5)

(c)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name,

e.g. call option
Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)

(ii)      Exercising

Product name,

e.g. call option
Number of securities Exercise price per unit (Note 5)

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)
Details Price per unit

(if applicable) (Note 5)

Ap21

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and 

any other person relating to the voting rights of any relevant securities under any option referred to 

on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to 

which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            Yes

Date of disclosure 27/04/2020
Contact name Société Générale - Disclosure team
Telephone number +33 1 42 14 92 74
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Ap23

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL 

ACT, 1997, TAKEOVER RULES, 2013

DETAILS OF OPEN POSITIONS

(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)

OPEN POSITIONS (Note 1)

Product name,

e.g. call option
Written, or purchased Number of relevant securities to which the option or derivative relates Exercise price (Note 2) Type, e.g. American, European etc. Expiry date
Listed Put Option Sale 40,000 175 American options 15/01/2021
Listed Put Option Sale 18,500 190 American options 15/01/2021

Notes

1.          Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

2.          For all prices and other monetary amounts, the currency must be stated.

For full details of disclosure requirements, see Rule 8 of the 

Rules. If in doubt, consult the Panel.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

ISESEIFSWESSEIL